Zhang Xueying, Li Ning, Chen Qiyi, Qin Huanlong
Intestinal Microenvironment Treatment Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Front Microbiol. 2021 Oct 7;12:700718. doi: 10.3389/fmicb.2021.700718. eCollection 2021.
Intestinal dysmotility is common in many diseases and is correlated with gut microbiota dysbiosis and systemic inflammation. Functional constipation (FC) is the most typical manifestation of intestinal hypomotility and reduces patients' quality of life. Some studies have reported that fecal micriobiota transplantation (FMT) may be an effective and safe therapy for FC as it corrects intestinal dysbiosis. This study was conducted to evaluate how FMT remodels the gut microbiome and to determine a possible correlation between certain microbes and clinical symptoms in constipated individuals. Data were retrospectively collected on 18 patients who underwent FMT between January 1, 2019 and June 30, 2020. The fecal bacterial genome was detected by sequencing the V3-V4 hypervariable regions of the 16S rDNA gene. Fecal short chain fatty acids (SCFAs) were detected by gas chromatography-mass spectrometry, and serum inflammatory factor concentrations were detected via enzyme-linked immunosorbent assay. Comparing the changes in fecal microbiome compositions before and after FMT revealed a significant augmentation in the alpha diversity and increased abundances of some flora such as Clostridiales, , and . This was consistent with the patients experiencing relief from their clinical symptoms. Abundances of other flora, including , were decreased, which might correlate with the severity of patients' constipation. Although no differences were found in SCFA production, the butyric acid concentration was correlated with both bacterial alterations and clinical symptoms. Serum IL-8 levels were significantly lower after FMT than at baseline, but IL-4, IL-6, IL-10, and IL-12p70 levels were not noticeably changed. This study showed how FMT regulates the intestinal microenvironment and affects systemic inflammation in constipated patients, providing direction for further research on the mechanisms of FMT. It also revealed potential microbial targets for precise intervention, which may bring new breakthroughs in treating constipation.
肠道动力障碍在许多疾病中都很常见,并且与肠道微生物群失调和全身炎症相关。功能性便秘(FC)是肠道动力不足最典型的表现,会降低患者的生活质量。一些研究报告称,粪便微生物群移植(FMT)可能是治疗FC的一种有效且安全的疗法,因为它可以纠正肠道菌群失调。本研究旨在评估FMT如何重塑肠道微生物群,并确定便秘个体中某些微生物与临床症状之间可能存在的相关性。回顾性收集了2019年1月1日至2020年6月30日期间接受FMT的18例患者的数据。通过对16S rDNA基因的V3-V4高变区进行测序来检测粪便细菌基因组。通过气相色谱-质谱法检测粪便短链脂肪酸(SCFA),并通过酶联免疫吸附测定法检测血清炎症因子浓度。比较FMT前后粪便微生物群组成的变化,发现α多样性显著增加,一些菌群如梭菌目等的丰度增加。这与患者临床症状缓解一致。包括等其他菌群的丰度降低,这可能与患者便秘的严重程度相关。虽然在SCFA产生方面未发现差异,但丁酸浓度与细菌变化和临床症状均相关。FMT后血清IL-8水平显著低于基线水平,但IL-4、IL-6、IL-10和IL-12p70水平没有明显变化。本研究展示了FMT如何调节便秘患者的肠道微环境并影响全身炎症,为进一步研究FMT的机制提供了方向。它还揭示了精确干预的潜在微生物靶点,这可能为便秘治疗带来新的突破。